Biomay

biomay.com
+43 1 7966296 100

Biomay AG

Lazarettgasse 19
1090 Wien
Austria

Phone

biomay.com
Contact
Profile News

About Biomay

Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens.

Read more about Biomay
Facts about Biomay
  • Industry : Pharma

Advertisement

Revolutionize your production: real-time Raman analysis for maximum efficiency
Revolutionize your production: real-time Raman analysis for maximum efficiency
Efficient inline analysis for liquids and solids
Efficient inline analysis for liquids and solids
User-friendly software for effortless Design of Experiments (DoE)
User-friendly software for effortless Design of Experiments (DoE)

News about Biomay

Biomay

27-Jan-2017 | science

Allergy Vaccine Successful

Biomay announced that a second Phase IIb study has been successfully completed with its third generation grass pollen allergy vaccine BM32. The study was ...

Read news
Biomay

10-Sep-2015 | research and development

Selective IgE immune apheresis hits market

Help for patients with IgE-mediated diseases

Read news
Biomay

09-Jun-2015 | research and development

Positive Phase IIB data for Biomay's grass pollen allergy vaccine

Biomay announced that the results of a landmark phase IIb study with its 3rd generation grass pollen allergy vaccine BM32 will be reported at the EAACI ...

Read news
Biomay

22-May-2015 | business & finance

VTU Technology and Biomay Have Signed License Agreement

Biomay to apply VTU Pichia strains for the production of recombinant allergens

Read news
Biomay

30-Jan-2015 | research and development

Biomay reports positve Phase IIB data with grass pollen allergy vaccine

Biomay announced that a landmark Phase IIb study has been successfully completed with its 3rd generation grass pollen allergy vaccine BM32. The study was ...

Read news
Biomay

15-Jun-2012 | research and development

Biomay's grass pollen allergy vaccine shows efficacy in phase IIa trial

Biomay AG announced promising results from a First-in-Man Phase IIa trial with its allergy vaccine BM32. The vaccine significantly reduced allergy-related ...

Read news
Show more news about Biomay

Here you will find Biomay AG